LTR Pharma (ASX:LTP) Change In Receivables : A$0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Change In Receivables?

LTR Pharma's change in receivables for the quarter that ended in Jun. 2023 was A$0.00 Mil. It means LTR Pharma's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

LTR Pharma's change in receivables for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means LTR Pharma's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

LTR Pharma's Accounts Receivable for the quarter that ended in Jun. 2023 was A$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. LTR Pharma's liquidation value for the six months ended in Jun. 2023 was A$7.12 Mil.

LTR Pharma Change In Receivables Historical Data

The historical data trend for LTR Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Change In Receivables Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Change In Receivables

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Change In Receivables	-	-	-

LTR Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 was A$0.00 Mil.

LTR Pharma (ASX:LTP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

LTR Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, LTR Pharma's accounts receivable are only considered to be worth 75% of book value:

LTR Pharma's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7.145	-	0.021	+	0.75 * 0	+	0.5 * 0
=	7.12

LTR Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines